Abstract 1326: Second generation androgen receptor signaling inhibitor resistant neuroendocrine like prostate cancer: A mechanistic study

Background:Failure of castration resistant prostate cancer patients to Androgen Receptor Signaling Inhibitor (ARSI) poses a major challenge in terms of therapeutic development. The heterogeneous nature of prostate cancer makes it difficult to stratify the treatment modalities. A multitude of variable pathological and genetic alterations induced by systemic treatment adds further to the therapeutic complexity. Upon continued exposure to...